Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab

(2018) J Hesselvig et al.   ACTA DERMATO-VENEREOLOGICA

Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks

(2018) Esther von Stebut et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy

(2017) G. Carretero et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-relevant treatment goals in psoriasis

(2015) Christine Blome et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study

(2015) Cassandra Chaptini et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The economic burden of psoriasis: a systematic literature review

(2014) Steven R Feldman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis

(2011) Stefanie Krenzer et al.   DERMATOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET